https://www.bioworld.com/rss en-us At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to move toward success – both at the level of individual companies and for indications as a whole. http://www.bioworld.com/articles/729826 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729826-with-improved-technologies-biomarkers-failed-drugs-may-come-into-their-own Vials, syringes, and pills The first day of Bio-Europe Spring, being held for the first time in Lisbon this year, featured panels on the partnering landscape in specific indications, as well as a more general panel on “Piecing Together the Therapeutic Landscape with Analyst Insights.” One theme of the panel was that by and large, large companies are looking for deals with companies that fit with their existing programs – but that such a fit can come in many forms. http://www.bioworld.com/articles/729814 Mon, 23 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729814-looking-for-tip-of-the-spear-science-via-m-and-as-investments Gold chain link engraved with "partnership" Precision psychiatry got some love at two quite different meetings this week, the European Congress of Neuropsychopharmacology’s New Frontiers meeting and BioEurope Spring. The New Frontiers Meeting, an annual two-day meeting dedicated to cutting-edge issues in brain disease research, focused on big-picture and scientific – at times almost philosophical – questions of how to get to a classification scheme for brain disorders that aligns with the underlying biology. http://www.bioworld.com/articles/706748 Tue, 19 Mar 2024 12:00:00 -0400 https://www.bioworld.com/articles/706748-at-long-last-a-path-to-remission-for-precision-psychiatry Two silhouettes with tangle, gear, spiral The increased availability of capital, greater access to talent, strong local governmental support and more focused attention on IP issues have increased the complexity of deals taking place between biotech and big pharma companies in China, according to Michelle Chan, chief business officer of Insilico Medicine Inc. http://www.bioworld.com/articles/695559 Tue, 28 Mar 2023 12:00:00 -0400 https://www.bioworld.com/articles/695559-bio-europe-spring-2023-chinas-appetite-for-more-complex-deals-is-growing The increased availability of capital, greater access to talent, strong local governmental support and more focused attention on IP issues have increased the complexity of deals taking place between biotech and big pharma companies in China, according to Michelle Chan, chief business officer of Insilico Medicine Inc, who spoke in a panel discussion on the topic of Asia-Pacific partnering at this year’s Bio-Europe Spring, in Basel, Switzerland on March 21. http://www.bioworld.com/articles/695497 Fri, 24 Mar 2023 12:00:00 -0400 https://www.bioworld.com/articles/695497-bio-europe-spring-2023-chinas-appetite-for-more-complex-deals-is-growing Are deals such as M&As between biotechs and big pharma becoming a thing of the past? That was a key question posed during the opening keynote at this year’s BIO-Europe Spring conference in Basel, Switzerland. Although Susanne Kreutz, global head of corporate and business development of Basel-based Novartis AG, doesn’t think this is the case, she told delegates that she believes M&A will increasingly focus in on “high-quality, high-impact, late-stage assets, where reimbursement is securable and where regulatory paths appear.” http://www.bioworld.com/articles/695290 Mon, 20 Mar 2023 12:00:00 -0400 https://www.bioworld.com/articles/695290-bio-europe-spring-2023-despite-funding-woes-biotechs-weather-the-storm-with-deals The challenging financial environment of 2022 will lead to an increase in partnerships, according to representatives of the two big Swiss biopharma companies, Roche Holding AG and Novartis AG. http://www.bioworld.com/articles/517359 Mon, 28 Mar 2022 12:00:00 -0400 https://www.bioworld.com/articles/517359-swiss-pharma-giants-look-for-partnerships-not-m-and-a-as-global-downturn-hits James Sabry, global head of pharma partnering, Roche James Sabry, global head of pharma partnering, Roche Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting. http://www.bioworld.com/articles/434084 Tue, 31 Mar 2020 14:37:00 -0400 https://www.bioworld.com/articles/434084-closing-panel-offers-covid-19-lessons-to-learn-from-china Coronavirus, question marks The five-day Bio-Europe Spring 2020 conference, possibly the first ever life sciences partnering event staged in an all-virtual format, ended on Friday, March 27, with high hopes that the industry would return to face-to-face interactions next year in Barcelona. http://www.bioworld.com/articles/434020 Fri, 27 Mar 2020 13:00:00 -0400 https://www.bioworld.com/articles/434020-conferences-go-virtual-postpone-as-covid-19-spreads-and-bio-europe-spring-wraps-up Virtual meetings illustration Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting. http://www.bioworld.com/articles/434027 Fri, 27 Mar 2020 12:00:00 -0400 https://www.bioworld.com/articles/434027-bio-europe-spring-2020 Flag of China and masks DUBLIN – Bio-Europe Spring’s virtual panel on the partnering dynamic between big pharma and microbiome-focused biotech firms was essentially an in-house webinar hosted by Seventure Partners, a Paris-based venture capital fund that has led the way in investing in microbiome-related therapeutics, diagnostics and other products. http://www.bioworld.com/articles/433981 Thu, 26 Mar 2020 13:00:00 -0400 https://www.bioworld.com/articles/433981-seventure-leads-think-in-on-microbiome-dealmaking Microbiome illustration At the beginning of this week, the digitally-delivered Bio-Europe Spring 2020 conference launched with 6,000 partnering meetings, 45 company presentations, more than 50 virtual exhibits and 12 panel discussions scheduled. http://www.bioworld.com/articles/433958 Wed, 25 Mar 2020 12:00:00 -0400 https://www.bioworld.com/articles/433958-partnering-plows-through-a-pandemic-with-the-restaged-virtual-bio-europe-spring-conference Business as usual only three months ago has transformed into health care industry overdrive as biopharma and med-tech companies scramble to test and scale-up treatments, vaccines and diagnostics to address COVID-19. http://www.bioworld.com/articles/433925 Tue, 24 Mar 2020 16:05:00 -0400 https://www.bioworld.com/articles/433925-moving-in-record-time-industry-government-investors-focus-on-one-mission-beat-covid-19 Coronavirus punch Before becoming the global head of Johnson & Johnson External Innovation, William Hait spent 30 years in academic medicine focused on oncology. Whenever he speaks to a group, the first question he asks is if there is anyone in the room that would like to get a disease. http://www.bioworld.com/articles/433913 Tue, 24 Mar 2020 12:00:00 -0400 https://www.bioworld.com/articles/433913-interrupting-disease-by-plugging-into-the-grid-and-pulling-down-innovation Laptop, stethoscope, medical icons, health professional DUBLIN – Bio-Europe Spring’s virtual panel on the partnering dynamic between big pharma and microbiome-focused biotech firms was essentially an in-house webinar hosted by Seventure Partners, a Paris-based venture capital fund that has led the way in investing in microbiome-related therapeutics, diagnostics and other products. http://www.bioworld.com/articles/433912 Tue, 24 Mar 2020 12:00:00 -0400 https://www.bioworld.com/articles/433912-seventure-leads-think-in-on-microbiome-dealmaking Microbiome illustration Business as usual only three months ago has transformed into health care industry overdrive as biopharma and med-tech companies scramble to test and scale-up treatments, vaccines and diagnostics to address COVID-19. http://www.bioworld.com/articles/433887 Mon, 23 Mar 2020 12:00:00 -0400 https://www.bioworld.com/articles/433887-moving-in-record-time-industry-government-investors-focus-on-one-mission-beat-covid-19 Coronavirus punch DUBLIN – For quite some time, cardiometabolic disease has been largely off the map for most small biotechs and for the venture capital investors that support them. Is that situation about to change? Maybe, maybe not was the mixed message arising from a Bio-Europe Spring 2020 virtual panel discussion on cardiometabolic disease. http://www.bioworld.com/articles/433881 Mon, 23 Mar 2020 11:55:00 -0400 https://www.bioworld.com/articles/433881-hunting-for-niches-in-cardiometabolic-disease-as-secarna-passes-dyslipidemia-milestone